Description of Medical ServiceDinutuximab beta is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response. Dinutuximab beta is an antibody directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. After binding, dinutuximab beta induces cell death through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.
Description of Medical ConditionNeuroblastoma is an embryonal tumour of the autonomic nervous system and usually occurs in young children. The tumours are found in sympathetic nervous system tissues, typically in the adrenal medulla or paraspinal ganglia and can present as mass lesions in the neck, chest, abdomen, or pelvis.
Reason for ApplicationHealth technology assessent
Medical Service TypeTherapeutic
Previous Application Number/sNot Applicable
Consultation SurveyConsultation Survey (PDF 561 KB)
Consultation Survey (Word 70 KB)
Public Summary DocumentPublic Summary Document (PDF 741 KB)
Public Summary Document (Word 596 KB)